News Sentiment

EVAX sentiment intelligence

Evaxion Biotech AS news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.17 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-7.0% over one week, -12.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

[6-K] Evaxion A/S Current Report (Foreign Issuer) | EVAX SEC Filing - Form 6-K

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -7.0% Price reacting lower
Trend fit Trend inactive -12.9% over four weeks
Fair value -77.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 35
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 10
Stock Titan 8
Market source 6
The Globe and Mail 5
TradingView 4
GlobeNewswire 3
TipRanks 3
dars.gov.et 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 16
Analyst action 4
Deals and strategy 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Investing.com Direct company coverage

Evaxion to present cytomegalovirus vaccine data at workshop

Evaxion A/S (NASDAQ:EVAX) will present preclinical data for its cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026. This data, which includes antigens effective in cellular and animal models, is intended to guide antigen sele

Tone
Positive 67/100
Event
Market update
Published
06 Jul 2026 15:41
Source
Investing.com
TradingView Direct company coverage

EVAX Forecast — Price Target — Prediction for 2027

This article provides a price target forecast for Evaxion A/S (EVAX) for the year 2027, based on analysis from 4 financial analysts. It includes sections for price target, analyst ratings, and EPS and revenue actuals and estimates, highlighting that the information is not investm

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 03:40
Source
TradingView
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Evaxion Biotech A/S (EVAX), noting that no specific risk assessment score is currently available, but the biotechnology industry average is 3.36. Key metrics such as the stock's beta (0.26), indicating underperformance in rising markets

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 02:41
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evaxion Biotech A/S (EVAX), highlighting its current price momentum score of 3.95 and positioning the stock between resistance at $3.85 and support at $2.65 for range-bound swing trading. It details various technical indicators like M

Tone
Negative 37/100
Event
Market update
Published
18 Jun 2026 18:40
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evaxion Biotech A/S (EVAX) has an earnings forecast score of 8.00, ranking 165 out of 389 in its industry. Analysts have set an average price target of $11.00, with a consensus "Buy" rating based on 4 analysts. The company's stock closed at $3.050, showing an 8.13% decrease on Ju

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 18:10
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey is a placeholder for Evaxion Biotech A/S (EVAX) revenue breakdown information. It indicates that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides general

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 01:40
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Evaxion Biotech A/S (EVAX) dividends and stock splits. It notes that the company has not distributed any dividends in the past five years. However, it lists several stock merger events with varying ratios in late 2024 and early 2024.

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 00:40
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Evaxion Biotech A/S (EVAX), listing major shareholders such as Merck & Co Inc and Merck Sharp & Dohme Corporation, along with their respective proportions. It also presents institutional shareholding data from Q1 2023 to Q1 2026,

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 00:40
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Institutional Confidence

Evaxion Biotech A/S (EVAX) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.88%, a 48.82% increase quarter-over-quarter. James Simons is the largest

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 18:10
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Financial Health: Profitability & Balance Sheet Analysis

Evaxion Biotech A/S (EVAX) currently holds a financial score of 7.14, ranking 148th out of 388 companies in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's financial overview sections, including Quality

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:41
Source
TradingKey
TradingKey Direct company coverage

Evaxion Biotech A/S (EVAX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Evaxion Biotech A/S (EVAX), noting its current valuation score of 9.76, ranking 15th within the Biotechnology & Medical Research industry. It highlights the stock's P/E ratio is -15.96, which is significantly below its recent high and

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:41
Source
TradingKey
Finviz Direct company coverage

EVAX - Evaxion A/S ADR Stock Price and Quote

This article provides comprehensive stock information for Evaxion A/S (EVAX), an ADR engaged in immunotherapy development. It details the company's latest stock price, financial metrics, analyst ratings, and a chronological list of recent news and press releases highlighting thei

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jun 2026 12:11
Source
Finviz
TradingKey Direct company coverage

Evaxion Biotech A/S EVAX

This page provides an overview of Evaxion Biotech A/S (EVAX) stock performance, showing its current price of 4.080 USD, a slight increase of 0.49%. The company has a market capitalization of 34.03M and its stock information is delayed by 15 minutes. The page also includes section

Tone
Neutral 50/100
Event
Market update
Published
17 May 2026 19:10
Source
TradingKey
Stock Titan Direct company coverage

AI-picked cancer vaccine targets triggered immune response 86% of the time

Evaxion (NASDAQ: EVAX) announced positive Phase 2 data for its personalized cancer vaccine, EVX-01, showing that its AI-Immunology™ platform accurately identified vaccine targets that triggered tumor-specific immune responses in 86% of cases. The vaccine, tested in combination wi

Tone
Positive 76/100
Event
Market update
Published
11 May 2026 15:09
Source
Stock Titan